Close

Anti-ELAVL4 T cell receptor (A6), pCDTCR1 (TCR-YC0349)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

A6 recognizes the HTLV-1 Tax Ag presented by HLA-A2 (positions 11–19 of the Tax protein; sequence LLFGYPVYV). A6 also recognizes a self Ag from an immunodominant region of the human neuronal protein HuD (positions 87–95; sequence LGYGFVNYI). T cell recognition of epitopes from HuD have been suggested to play a role in the neurologic disorder human T cell leukemia virus-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP), a demyelinating autoimmune disease affecting a minority of HTLV-1–infected individuals.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • ELAVL4
  • Target Species
  • Human
  • Epitope
  • LGYGFVNYI
  • Format
  • Non-Modified TCR
  • Allele
  • HLA-A2
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • A6
  • Host Species
  • Human

Target

  • Introduction
  • ELAVL4 (ELAV Like RNA Binding Protein 4) is a Protein Coding gene. Diseases associated with ELAVL4 include Hallucinogen Abuse and Paraneoplastic Neurologic Disorders. Gene Ontology (GO) annotations related to this gene include nucleic acid binding and nucleotide binding. An important paralog of this gene is ELAVL2.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human anti-ELAVL4 T cell receptor (A6), pCDTCR1 (TCR-YC0349). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.